Cargando…

Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review

The evolution of articular cartilage repair procedures has resulted in a variety of cell-based therapies that use both autologous and allogeneic mesenchymal stromal cells (MSCs). As these cells are increasingly available and show promising results both in vitro and in vivo, cell-based strategies, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Vonk, Lucienne A., de Windt, Tommy S., Slaper-Cortenbach, Ineke C. M., Saris, Daniël B. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430904/
https://www.ncbi.nlm.nih.gov/pubmed/25976213
http://dx.doi.org/10.1186/s13287-015-0086-1
_version_ 1782371249444356096
author Vonk, Lucienne A.
de Windt, Tommy S.
Slaper-Cortenbach, Ineke C. M.
Saris, Daniël B. F.
author_facet Vonk, Lucienne A.
de Windt, Tommy S.
Slaper-Cortenbach, Ineke C. M.
Saris, Daniël B. F.
author_sort Vonk, Lucienne A.
collection PubMed
description The evolution of articular cartilage repair procedures has resulted in a variety of cell-based therapies that use both autologous and allogeneic mesenchymal stromal cells (MSCs). As these cells are increasingly available and show promising results both in vitro and in vivo, cell-based strategies, which aim to improve ease of use and cost-effectiveness, are progressively explored. The use of MSCs in cartilage repair makes it possible to develop single-stage cell-based therapies. However, true single-stage procedures rely on one intervention, which will limit cell sources to fraction concentrates containing autologous MSCs or culture-expanded allogeneic MSCs. So far, it seems both autologous and allogeneic cells can safely be applied, but clinical studies are still ongoing and little information on clinical outcome is available. Further development of cell-based therapies may lead to clinical-grade, standardized, off-the-shelf products with easy handling for orthopedic surgeons. Although as of yet no preclinical or clinical studies are ongoing which explore the use of induced pluripotent stem cells for cartilage repair, a good manufacturing practice-grade induced pluripotent stem cell line might become the basis for such a product in the future, providing that cell fate can be controlled. The use of stem cells in clinical trials brings along new ethical issues, such as proper controls and selecting primary outcome measures. More clinical trials are needed to estimate detailed risk-benefit ratios and trials must be carefully designed to minimize risks and burdens for patients while choosing outcome measures that allow for adequate comparison with results from similar trials. In this review, we discuss the different aspects of new stem cell-based treatments, including safety and ethical issues, as well as provide an overview of current clinical trials exploring these approaches and future perspectives.
format Online
Article
Text
id pubmed-4430904
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44309042015-05-15 Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review Vonk, Lucienne A. de Windt, Tommy S. Slaper-Cortenbach, Ineke C. M. Saris, Daniël B. F. Stem Cell Res Ther Review The evolution of articular cartilage repair procedures has resulted in a variety of cell-based therapies that use both autologous and allogeneic mesenchymal stromal cells (MSCs). As these cells are increasingly available and show promising results both in vitro and in vivo, cell-based strategies, which aim to improve ease of use and cost-effectiveness, are progressively explored. The use of MSCs in cartilage repair makes it possible to develop single-stage cell-based therapies. However, true single-stage procedures rely on one intervention, which will limit cell sources to fraction concentrates containing autologous MSCs or culture-expanded allogeneic MSCs. So far, it seems both autologous and allogeneic cells can safely be applied, but clinical studies are still ongoing and little information on clinical outcome is available. Further development of cell-based therapies may lead to clinical-grade, standardized, off-the-shelf products with easy handling for orthopedic surgeons. Although as of yet no preclinical or clinical studies are ongoing which explore the use of induced pluripotent stem cells for cartilage repair, a good manufacturing practice-grade induced pluripotent stem cell line might become the basis for such a product in the future, providing that cell fate can be controlled. The use of stem cells in clinical trials brings along new ethical issues, such as proper controls and selecting primary outcome measures. More clinical trials are needed to estimate detailed risk-benefit ratios and trials must be carefully designed to minimize risks and burdens for patients while choosing outcome measures that allow for adequate comparison with results from similar trials. In this review, we discuss the different aspects of new stem cell-based treatments, including safety and ethical issues, as well as provide an overview of current clinical trials exploring these approaches and future perspectives. BioMed Central 2015-05-15 /pmc/articles/PMC4430904/ /pubmed/25976213 http://dx.doi.org/10.1186/s13287-015-0086-1 Text en © Vonk et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Vonk, Lucienne A.
de Windt, Tommy S.
Slaper-Cortenbach, Ineke C. M.
Saris, Daniël B. F.
Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title_full Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title_fullStr Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title_full_unstemmed Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title_short Autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? Where are we headed in cartilage repair and why: a concise review
title_sort autologous, allogeneic, induced pluripotent stem cell or a combination stem cell therapy? where are we headed in cartilage repair and why: a concise review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430904/
https://www.ncbi.nlm.nih.gov/pubmed/25976213
http://dx.doi.org/10.1186/s13287-015-0086-1
work_keys_str_mv AT vonkluciennea autologousallogeneicinducedpluripotentstemcelloracombinationstemcelltherapywhereareweheadedincartilagerepairandwhyaconcisereview
AT dewindttommys autologousallogeneicinducedpluripotentstemcelloracombinationstemcelltherapywhereareweheadedincartilagerepairandwhyaconcisereview
AT slapercortenbachinekecm autologousallogeneicinducedpluripotentstemcelloracombinationstemcelltherapywhereareweheadedincartilagerepairandwhyaconcisereview
AT sarisdanielbf autologousallogeneicinducedpluripotentstemcelloracombinationstemcelltherapywhereareweheadedincartilagerepairandwhyaconcisereview